IMP
Dược phẩm Imexpharm ·HOSE ·2026Q1
▲ Slightly positive
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, IMP shows mild improvement in both revenue and margins, but the magnitude of change is narrow — profit is at an all-time high. This signal only becomes convincing if the improvement widens in coming periods.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.2 | 640.8 | 573.6 | 632.7 | 594.1 | 652.1 | 544.7 | 517.2 | 491.1 | 608.2 | 466.9 | 439.7 |
| Growth | -15% | +12% | -9% | +7% | -9% | +20% | +5% | +5% | -19% | +30% | +6% | — |
| Net Income | 82.0 | 107.5 | 76.9 | 90.3 | 74.5 | 120.6 | 72.4 | 65.9 | 61.9 | 72.3 | 69.7 | 79.7 |
| Net Margin | 15.02% | 16.77% | 13.41% | 14.27% | 12.53% | 18.50% | 13.29% | 12.75% | 12.61% | 11.90% | 14.93% | 18.12% |
Drivers of IMP's profit
Net profit attributable to parent increased vs last year, mainly helped by higher gross profit. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by lower selling expenses. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE is broadly flat at 15.4% — the components are offsetting one another.
Is the profit sustainable?
Margins are improving and earnings quality is solid — a durable foundation for ROE.
What is driving the margin?
Net margin edged up to 14.90%, rising 0.5pp. Core operating signals are improving as Gross margin rose 2.1pp are enough to offset pressure from SG&A / Revenue rose 1.4pp (with lingering pressure from Net financial result / Revenue fell 0.1pp and Other profit / Revenue fell 0.0pp).
The improvement comes from core operations — this is a high-quality margin expansion.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Evaluate capital, asset, and working-capital efficiency.
Is capital being deployed efficiently?
ROIC stands at 14.69%, broadly flat versus the same period. That translates to 14.69 in after-tax operating profit for every 100 units of operating capital. NOPAT margin rose 0.5pp, but capital turnover broadly stable, while invested capital rose by 173bn — the two factors are offsetting each other, keeping overall ROIC nearly unchanged.
Overall ROIC is flat while internal components are moving — watch which side becomes dominant in coming periods.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
Capital structure is conservative with low leverage — liabilities at 0.21x equity, net debt at 0.05x equity.
Inventory ended the period at 677.7bn, roughly 24.4% of total assets.
Over the last 12 months, working capital released 247.5bn of cash, mainly thanks to lower receivables and lower inventories. Pressure from lower payables only partly offset that benefit.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 5.9 days versus the same period last year. The main moves came from DIO fell 8.6 days, DSO rose 4.3 days, and DPO rose 1.6 days.
Improvement comes mainly from faster inventory turnover — watch whether this trend persists in coming periods.
Watchpoints
CCC stands at 207.1 days, suggesting that working capital remains tied up for a relatively long operating cycle.
DSO increased by +4.3 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Financial risk is low — leverage is safe, both CFO and FCF are positive.
Leverage & Liquidity
Leverage looks fairly comfortable, with net debt / equity at 0.05x and interest coverage at 11.88x.
At present, short-term debt accounts for 50.0% of total debt, cash equals 37.9% of debt, and total debt stands at 200.0bn.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 54.2bn in 2025, against investing cash flow of -76.6bn.
Post-investment cash flow was negative +22.4bn. Financing cash flow was positive +49.7bn.
CFO / net income was 0.82x.
After spending +14.7bn on fixed-asset investment, the business generated trailing free cash flow of +277.9bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is entering a broader improvement phase — not just stronger earnings but better operating quality as well. Margin, ROIC, and cash flow all improving shows the business is growing in a cleaner and more efficient way than before. Notably, the improvement trend has been confirmed across multiple cycles, from margin to capital efficiency and cash generation. The residual risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 207 days.
Improvement: earnings conversion looks more confirmed, with CFO / net income at 0.82x.
Key risk: working capital remains tied up for too long, with cash cycle at 207.1 days.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
|
Net Revenue
|
2,441.1 | 2,205.1 | 1,994.0 | 1,643.7 | 1,266.6 |
|
Cost of Goods Sold
|
1,439.5 | 1,349.6 | 1,183.5 | 946.4 | 0.0 |
|
Gross Profit
|
1,001.6 | 855.6 | 810.5 | 697.4 | 488.0 |
|
Financial Expenses
|
40.1 | 25.2 | 31.5 | 29.4 | -18.0 |
|
Selling Expenses
|
378.3 | 312.1 | 309.9 | 269.0 | -181.3 |
|
General and Administrative Expenses
|
160.8 | 128.3 | 119.6 | 131.8 | -72.6 |
|
Operating Profit
|
445.0 | 403.3 | 374.4 | 290.6 | 234.5 |
|
Profit Before Tax
|
446.2 | 404.2 | 377.3 | 291.4 | 238.9 |
|
Net Income
|
349.1 | 320.9 | 299.6 | 223.5 | 189.1 |
|
Profit Attributable to Parent
|
349.1 | 320.9 | 299.6 | 223.5 | 189.1 |
|
Earnings per Share
|
1,976.00 | 1,932.00 | 3,637.00 | 2,951.00 | 2,600.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.